$4.08
0.11[2.77%]
At close: Apr 10
$4.08
0[0.00%]
PreMarket: 9:20AM EDT
GT Biopharma
(NASDAQ:GTBP)GT Biopharma Stock (NASDAQ:GTBP), Analyst Ratings, Price Targets, Predictions
GT Biopharma Inc has a consensus price target of $3.5, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., EF Hutton, and HC Wainwright & Co. on August 8, 2023, August 7, 2023, and June 5, 2023. With an average price target of $4 between HC Wainwright & Co., EF Hutton, and HC Wainwright & Co., there's an implied -1.96% downside for GT Biopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for GT Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/08/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | 22.55% | HC Wainwright & Co. | Robert Burns | → $150 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | -50.98% | EF Hutton | Tony Butler | → $60 | Reiterates | Hold → Hold | Get Alert |
| 06/05/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | 22.55% | HC Wainwright & Co. | Robert Burns | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | 22.55% | HC Wainwright & Co. | Robert Burns | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | -50.98% | EF Hutton | Tony Butler | → $60 | Reiterates | Hold → Hold | Get Alert |
| 04/03/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | 22.55% | HC Wainwright & Co. | Robert Burns | → $150 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | -50.98% | EF Hutton | Tony Butler | → $60 | Reiterates | → Hold | Get Alert |
| 01/05/2023 | GTBP | Buy Now | GT Biopharma | $4.08 | -50.98% | EF Hutton | Tony Butler | → $60 | Initiates | → Hold | Get Alert |
| 09/13/2022 | GTBP | Buy Now | GT Biopharma | $4.08 | 22.55% | HC Wainwright & Co. | Robert Burns | $750 → $150 | Maintains | Buy | Get Alert |
| 05/24/2021 | GTBP | Buy Now | GT Biopharma | $4.08 | 512.75% | HC Wainwright & Co. | Robert Burns | → $750 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for GT Biopharma (GTBP)?
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $5.00 expecting GTBP to rise to within 12 months (a possible 22.55% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GT Biopharma (GTBP)?
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by HC Wainwright & Co., and GT Biopharma reiterated their buy rating.
When was the last upgrade for GT Biopharma (GTBP)?
There is no last upgrade for GT Biopharma.
When was the last downgrade for GT Biopharma (GTBP)?
There is no last downgrade for GT Biopharma.
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating GT Biopharma (GTBP) correct?
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $5.00. The current price GT Biopharma (GTBP) is trading at is $4.08, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.